The spectrum of Evans syndrome in adults: New insight into the disease based on the analysis of 68 cases

Blood

Volumn 114, Issue 15, 2009, Pages 3167-3172

  Michel, Marc ^a   Chanet, Valérie ^b   Dechartres, Agnès ^c   Morin, Anne Sophie ^a   Piette, Jean Charles ^d   Cirasino, Lorenzo ^e   Emilia, Giovanni ^f   Zaja, Francesco ^g   Ruggeri, Marco ^h   Andrès, Emmanuel ⁱ   Bierling, Philippe ^j   Godeau, Bertrand ^a   Rodeghiero, Francesco ^h  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^c INSERM   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e OSPEDALE NIGUARDA CA GRANDA   (Italy)

^f UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^g UNIVERSITY HOSPITAL OF UDINE   (Italy)

^h SAN BORTOLO HOSPITAL   (Italy)

ⁱ UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^j ETABLISSEMENT FRANÇAIS DU SANG   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DANAZOL; DAPSONE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; MYCOPHENOLIC ACID; PREDNISOLONE; PREDNISONE; RITUXIMAB; ANTINEOPLASTIC AGENT; CORTICOSTEROID; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; CARDIOVASCULAR RISK; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; FEMALE; FOLLOW UP; HUMAN; IMMUNE DEFICIENCY; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SPLENECTOMY; SYSTEMIC LUPUS ERYTHEMATOSUS; T CELL LYMPHOMA; AGE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFORMATION PROCESSING; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEUTROPENIA; ONSET AGE; PATHOLOGY; RISK FACTOR; SURVIVAL RATE; SYNDROME;

ADRENAL CORTEX HORMONES; AGE FACTORS; AGE OF ONSET; AGED; AGED, 80 AND OVER; ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DATA COLLECTION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; NEUTROPENIA; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; SPLENECTOMY; SURVIVAL RATE; SYNDROME;

EID: 70350483030     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-04-215368     Document Type: Article

References (38)

1. Evans RS, Takahashi K, Duane RT, Payne R, LiuC. Primary thrombocytopenic purpura and acquired haemolytic anemia; evidence for a common etiology. Arch Int Med. 1951;93(1):341-344.
2. Evans RS, Duane RT. Acquired hemolytic anemia; the relation of erythrocyte antibody production to activity of the disease; the significance of thrombocytopenia and leukopenia. Blood. 1949;4(11):1196-1213.
3. Delezé M, Oria CV, Alarcon-Segovia D. Occurrence of both hemolytic anemia and thrombocytopenic purpura (Evans' syndrome) in systemic lupus erythematosus. Relationship to antiphospholipid antibodies. J Rheumatol. 1988;15(4):611-615. (Pubitemid 18135191)
4. García-Muñoz R, Rodriguez-Otero P, Pegenaute C, et al. Splenic marginal zone lymphoma with Evans' syndrome, autoimmunity, and peripheral gamma/delta T cells. Ann Hematol. 2009;88(2):177-178.
5. Hauswirth AW, Skrabs C, Schützinger C, et al. Autoimmune thrombocytopenia in non-Hodgkin's lymphomas. Haematologica. 2008;93(3):447-450.
6. Michel M, Chanet V, Galicier L, et al. Autoimmune thrombocytopenic purpura and common variable immunodeficiency: analysis of 21 cases and review of literature. Medicine. 2004;83(4):254-263. (Pubitemid 38955448)
7. Teachy DT, Manno CS, Axsom KM, et al. Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). Blood. 2005;105(6):2443-2448.
8. Norton A, Roberts I. Management of Evans syndrome. Br J Haematol. 2005;132(2):125-137.
9. Ng SC. Evans syndrome: a report on 12 patients. Clin Lab Haemat. 1992;14(3):189-193.
10. Savasan S, Warrier I, Ravindranath Y. The spectrum of Evans' syndrome. Arch Dis Child. 1997;77(3):245-248.
11. Pegels JG, Helmerhorst FM, Van Leuwen EF, van de Plas-van Dalen C, Engelfriet CP, von dem Borne AE. The Evans syndrome: characterization of the responsible autoantibodies. Br J Haematol. 1982;51(3):445-450.
12. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guide developed by explicit methods for the American Society of Hematology. Blood. 1996;88(1):3-40.
13. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum. 1997;40(9):1725.
14. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306.
15. Vitali C, Bombardieri S, Moutsopoulos HM. Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum. 1993;36(3):340-347. (Pubitemid 23090601)
16. Wang W, Herrod H, Pui CH, Presbury G, Wilimas J. Immunoregulatory abnormalities in Evans syndrome. Am J Hematol. 1983;15(4):381-390.
17. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura (ITP) of adults and children: report from an International Working Group. Blood. 2009;113(11):2386-2393.
18. Gerhrs BS, Friedberg RC. Autoimmune haemolytic anemia. Am J Hematol. 2002;69(4):258-271.
19. Ekström Smedby K, Vajdic CM, Falster M, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood. 2008;111(8):4029-4038.
20. Thieblemont C, Felman P, Berger F, et al. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymphoma. 2002;3(1):41-47. (Pubitemid 34885046)
21. Genty I, Michel M, Hermine O, Schaeffer A, Godeau B, Rochant H. Caractéristiques des anémies hémolytiques auto-immunes de l'adulte: analyse rétrospective d'une série de 83 patients. Rev Med Int. 2002;23(11):901-909. (Pubitemid 35397865)
22. Magerus-Chatinet A, Stolzenberg MC, Loffredo MS, et al. FAS-L, IL-10, and double-negative CD4-CD8-TCR alpha/beta+ T cells are reliable markers of ALPS associated with FAS loss of function. Blood. 2009;113(13):3027-3030.
23. Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood. 1999;94(3):909-913. (Pubitemid 29361821)
24. Mathew P, Chen C, Wang W. Evans syndrome: results of a national survey. J Ped Hem Onc. 1997;19(5):433-435. (Pubitemid 28076488)
25. Blouin P, Auvrignon A, Pagnier A, et al. Evans' syndrome: a retrospective study from the ship (French Society of Pediatric Hematology and Immunology) (36 cases)[in French]. Arch Pediatr. 2005;12(11):1600-1607. (Pubitemid 41560908)
26. Pignon JM, Poirson E, Rochant H. Danazol in autoimmune haemolytic anemia. Br J Haematol. 1993;83(2):343-345.
27. Ahn YS. Efficacy of danazol in hematologic disorders. Acta Haematol. 1990;84(3):122-129.
28. Rodeghiero F, Ruggeri M. Is splenectomy still the gold standard for the treatment of chronic ITP? [editorial]. Am J Hematol. 2008;83(2):91.
29. Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol. 2004;125(2):232-239. (Pubitemid 38534976)
30. Bussone G, Ribeiro E, Dechartres A, et al. Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 cases. Am J Hematol. 2009;84(3):153-157.
31. Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune haemolytic anemia and Evans syndrome. Mayo Clinic Proceed. 2003;78(11):1340-1346. (Pubitemid 37337779)
32. Bader-Meunier B, Aladjidi N, Bellman F, et al. Rituximab therapy for childhood Evans syndrome. Haematologica. 2007;92(12):1691-1694. (Pubitemid 350248250)
33. Narat S, Gandla J, Hoffbrand AV, Hughes RG, Mehta AB. Rituximab in the treatment of refractory autoimmune cytopenias. Haematologica. 2005;90(9):1273-1274. (Pubitemid 41375288)
34. Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol. 2008;141(2):149-169.
35. Hershko C, Sonnenblick M, Ashkenazi J. Control of steroid-resistant autoimmune haemolytic anemia by cyclosporine. Br J Haematol. 1990;76(3):436-437. (Pubitemid 20367859)
36. Emilia G, Messora C, Longo G, Bertesi M. Longterm salvage treatment by cyclosporin in refractory autoimmune haematological disorders. Br J Haematol. 1996;93(2):341-344. (Pubitemid 26148737)
37. Howard J, Hoffbrand AV, Prentice HG, Mehta A. Mycophenolate mofetil for the treatment of refractory autoimmune haemolytic anemia and autoimmune thrombocytopenic purpura. Br J Haematol. 2002;117(3):712-715. (Pubitemid 34539252)
38. Kotb R, Pinganaud C, Trichet C, et al. Efficacy of mycophenolate mofetil in adult refractory autoimmune cytopenias: a single center preliminary study. Eur J Haematol. 2005;75(1):60-64 (Pubitemid 40873963)